Drugs / HSK36273
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05742126 | Apr → Sep 2022 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05602129 | Nov 2022 → Oct 2023 | — | Haisco Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK36273 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05742126 ↗ |
| Route | Intravenous | “Multiple continuous IV infusion ascending doses” NCT05742126 ↗ |